Sialix Obtains $400,000 Series B Round

  • Feed Type
  • Date
    10/11/2012
  • Company Name
    Sialix
  • Mailing Address
    One Cambridge Center 6th Floor Cambridge, MA 02142
  • Company Description
    Sialix is developing products based on new biological discoveries of non-human sialic acids, their dietary role and inflammatory consequences, and their potential impact on cancer, cardiovascular, and other inflammatory-mediated diseases. Sialix is actively pursuing the parallel development of two complementary product development programs: (1) an oncology therapeutic for solid tumors, such as ovarian, breast, and colon cancer, (2) a prophylactic nutritional supplement to prevent chronic inflammation associated with ingestion of a non-human sialic acid which is found in red meat and certain other dietary sources. Chronic inflammation has been linked to the development and progression of cancer, heart attacks, strokes, obesity, and diabetes, as well as other chronic inflammatory conditions.
  • Website
    http://www.sialix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $400,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.